DBVT vs ERC Comparison

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.